<unk>  is a three-drug combination of<unk>  (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir<unk>  (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen that is FDA approved for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of<unk><unk> /emtricitabine/tenofovir<unk><unk> . There is a Black Box Warning for this drug as shown here.  Common adverse reactions include diarrhea, nausea, and headache.
Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate
Dolutegravir / rilpivirine
Bictegravir / emtricitabine / tenofovir alafenamide
Ledipasvir / sofosbuvir
Sofosbuvir / velpatasvir
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Emtricitabine rilpivirine tenofovir
Atazanavir and cobicistat